Sumitomo Pharma
Sumitomo Pharma Co., Ltd., a prominent player in the global pharmaceutical industry, is headquartered in Japan (JP) and operates extensively across Asia, Europe, and North America. Founded in 1897, the company has a rich history marked by significant milestones, including advancements in research and development that have positioned it as a leader in innovative healthcare solutions. Specialising in prescription pharmaceuticals, Sumitomo Pharma focuses on areas such as central nervous system disorders, oncology, and regenerative medicine. Its unique approach to drug development, emphasising both quality and efficacy, has led to the creation of several groundbreaking therapies. With a strong market presence and a commitment to improving patient outcomes, Sumitomo Pharma continues to achieve notable recognition within the industry, solidifying its reputation as a trusted name in healthcare.
DitchCarbon Score
How does Sumitomo Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sumitomo Pharma's score of 31 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Sumitomo Pharma's reported carbon emissions
In 2023, Sumitomo Pharma reported significant carbon emissions, with Scope 2 emissions at approximately 26,827,000 kg CO2e and Scope 3 emissions reaching about 356,214,000 kg CO2e. The company has not disclosed any Scope 1 emissions for this year. Over the previous years, emissions have fluctuated, with total emissions peaking at approximately 725,190,000 kg CO2e in 2020, which included Scope 1 emissions of about 19,514,000 kg CO2e, Scope 2 emissions of approximately 38,753,000 kg CO2e, and Scope 3 emissions of around 393,124,000 kg CO2e. Sumitomo Pharma has not set specific reduction targets or initiatives as part of their climate commitments, indicating a potential area for improvement in their sustainability strategy. The absence of documented reduction targets suggests that while the company is aware of its emissions, it may not yet have formalised a comprehensive plan to address them. As the pharmaceutical industry increasingly focuses on sustainability, Sumitomo Pharma's future commitments will be crucial in aligning with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Get Started| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 41,805,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - |
| Scope 2 | 38,906,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 35,270,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sumitomo Pharma is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
